Ken-ichi Hanada, M.D., Ph.D.

Ken-ichi Hanada, M.D., Ph.D.
Staff Scientist
Surgery Branch

Team Member of:

James C. Yang, M.D.

Dr. Hanada received M.D. degree at Tokyo Medical and Dental University and a Ph.D. at the University of Tokyo, Japan. He joined the Surgery Branch, NCI in 1997 as a visiting scientist and became a staff scientist in 2005. He has been involved in the basic studies of immune response to renal cell carcinoma and also in the development of clinical trials for renal cell carcinoma.

Areas of Expertise

renal cell carcinoma

Contact Info

Ken-ichi Hanada, M.D., Ph.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 3w-3840
Bethesda, MD 20892-1201
Ph: 240-858-3774
hanadak@mail.nih.gov

Selected Publications

  1. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.
    Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC.
    Cancer Res.. 72: 6119-29, 2012. [ Journal Article ]
  2. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors.
    Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA.
    J. Clin. Invest.. [Epub ahead of print], 2014. [ Journal Article ]
  3. Double or nothing on cancer immunotherapy.
    Hanada K, Restifo NP.
    Nat. Biotechnol.. 31: 33-4, 2013. [ Journal Article ]
  4. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes.
    Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA.
    Blood. 122: 1399-410, 2013. [ Journal Article ]
  5. aß T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities.
    Tikhonova AN, Van Laethem F, Hanada K, Lu J, Pobezinsky LA, Hong C, Guinter TI, Jeurling SK, Bernhardt G, Park JH, Yang JC, Sun PD, Singer A.
    Immunity. 36: 79-91, 2012. [ Journal Article ]

Dr. Hanada received M.D. degree at Tokyo Medical and Dental University and a Ph.D. at the University of Tokyo, Japan. He joined the Surgery Branch, NCI in 1997 as a visiting scientist and became a staff scientist in 2005. He has been involved in the basic studies of immune response to renal cell carcinoma and also in the development of clinical trials for renal cell carcinoma.